New automated process to simplify the manufacturing of gene-engineered NK Cells and Treg cells isolation
July 28, 2022
Natural killer (NK) cell and CAR NK cell-based immunotherapies show an enormous potential for the treatment of several diseases.
However, the isolation of NK cells can be challenging, and achieving a high purity of the NK cell population is an all-important first step. Clinical-grade natural killer (NK)cell isolation can be enabled in a two-step, fully automated manner within a closed system on the CliniMACS Prodigy. The LP-3-56 Process allows fully automated in vitro depletion of CD3 expressing cells with optional subsequen in vitro enrichment of human CD56 expressing cells Following this, isolated NK cells can either be applied directly, expanded for further use, or serve as starting material for NK cell engineering.
Regulatory T (Treg) cells are a specialized subpopulation of T cells that act to suppress immune responses, thereby maintaining homeostasis and
self-tolerance. To address the variety of Treg cell applications, Miltenyi Biotec provides a broad range of tools for clinical use. By combining the CliniMACS Cell Manufacturing Platform with MACS GMP Products and our GMP-compliant cell sorter MACSQuant® Tyto®, you can now significantly enhance your clinical-grade Treg cell manufacturing possibilities.